AXIOS November 19, 2024
Between Robert F. Kennedy Jr. and Vivek Ramaswamy, the incoming Trump administration has divergent views on regulating the pharmaceutical industry.
Why it matters: Both influential MAGA allies say there are deep problems with America’s drug development system. But RFK Jr., the Health and Human Services secretary designee, is calling for more oversight of drugs and vaccines and diminished federal funding for R&D.
- Ramaswamy, a biotech entrepreneur who will lead a new “Department of Government Efficiency” with Elon Musk, is a small government aficionado who’s called for fewer barriers to bringing drugs to market.
Their differences add another layer of uncertainty for pharmaceutical companies trying to navigate what could be dizzying changes in the new administration.
Where it stands:...
Today's Sponsors
Today's Sponsor